FIRST TRIMESTER ULTRASOUND : AN EARLY SCREENING TOOL FOR FETAL STRUCTURAL AND CHROMOSOMIC ABNORMALITIES.

##plugins.themes.academic_pro.article.sidebar##

Published Dec 9, 2009
Download
pdf
Vol. 87 No. 12 (2009): Issue Dec 2009

##plugins.themes.academic_pro.article.main##

Dalenda Chelli
Inès Gaddour
Inès Najar
Fethia Boudaya
Béchir Zouaoui
Ezzeddine Sfar
Habiba Chaabouni
Hèla Chelli
Channoufi Mohamed B

Abstract

Background: Prenatal diagnosis has been greatly expanded in recent years. Many biological and sonographic criteria participated in the development of fetal medicine.
Aim : Analyze the contribution of first trimester ultrasound in prenatal diagnosis of aneuploidy and early fetal malformations, and its impact on the strategy of prevention of disability.
Methods: A prospective longitudinal descriptive study including all women who did a first trimester ultrasound during their pregnancy. We evaluated the detection rate of malformations and chromosomal abnormalities of the morphological embryonary study and nuchal translucency. These tests were then confronted with the results of fetal samples and the outcome of pregnancy.
Results: 593 ultrasound examinations were performed. The average age of pregnant women was 32.7 years. The mini-morphological ultrasound study revealed 26 abnormalities (3 major lethal malformations, 5 cystic hygroma and 18 increased nuchal translucency). Chromosomal abnormalities were found in six cases.
The first trimester ultrasound has ensured the detection of 2/3 of total aneuploidies of the study.
Conclusion: The first trimester ultrasound allows early detection of a large number of aneuploidies and fetal malformations.

Keywords:

First trimester ultrasound, Nucal transluscency, Cystic hygroma, Maternal serum screening

##plugins.themes.academic_pro.article.details##

References

  1. Scharzler P, Carvalho Js, Senat MV et al. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in a unselect population. Br J Obstet Gynecol 1999; 106:1029-34.
  2. Herman A, Marymon R, Dreazen E, Caspi E. Nuchal translucency audit: a novel image-scoring method. Ultrasound Obstet Gynecol 1998; 12: 398-403.
  3. Bourgeot P. Échographie du premier trimestre : apport au diagnostic des embryopathies et des anomalies chromosomiques. Feuillets de radiologie 2002; 5: 374-383.
  4. Weingertner A S, FAVRE R. EMC Obstétrique. Clarté nucale 2009: 5-018-A-35.
  5. Ducrame G, Graesslin O, Alanio E, Bige V, Gaillard D, Gabriel R. Hyperclarté nucale et hygroma cervical au premier trimestre de la grossesse: diagnostic prénatal et devenir néonatal. Gynecol Obstet Fertil 2005;33:750-4.
  6. Hafner E, Schuchter K, Liebhart E. Results of routine fetal nuchal translucency measurement at weeks 10-13 in 4233 unselected pregnant women. Prenat Diagn 1998; 18: 29-34
  7. Nicolaides KH. Screening for chromosomal defects. Ultrasound Obstet Gynecol 2003; 21: 313-21.
  8. Rozenberg P. Dépistage de la trisomie 21 par l'échographie. Gynecol Obstet & Fertilité 2005; 33: 526-32.
  9. Broussin B, Sarramon M. La clarté nucale : technique de mesure et signification. J Radiol 2002; 83: 1891-8.
  10. Snijders Rj, Thom Ea, Zachary JM. First trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002; 19: 353-9.
  11. Wald NJ. Translucency. Ultrasound Obstet Gynecol 1995; 6: 330-3.
  12. Hafner E, Schuchter K, Philipp K. Screening for chromosomal abnormalities in an unselected population by fetal nuchal. Médecine foetale et néonatale 2001 :145-8.
  13. Snijders Rjm, Johnson S, Sebire N. First trimester ultrasound screening for chromosomal defects. Ultrasound Obstet Gynecol 1996; 7: 216-26.
  14. Cicero S, Curcio P, Papa Georghiou A, Sonek J, Nicolaides KJ. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001; 358: 1665-7.
  15. Matias a, gomes c, flack n, montenegro n, nicolaides kh. Screening for chromosomal abnormalities at 10-14 weeks: the role of ductus venosus blood flow. Ultrasound Obstet Gynecol 1998; 12: 380-4.
  16. wald nj, kennard a, hackshaw a, mcguire A. Antenatal screening for Down's syndrome. J Med Screen 1997; 4: 181-246.
  17. Muller F. Dépistage de la trisomie 21 par les marqueurs sériques. EMC Gynécologie Obstétrique 2005; 2: 209-16.
  18. Audiber F, Dommergues M. Dépistage de la trisomie 21 : clarté nucale et/ou marqueurs sériques ? Gynecol Obstet Fertil 2001; 29: 599-604.
  19. Audiber F, Mairovitz V, Frydman R. Les alternatives à l'amniocentèse pour age maternel. Gynecol Obstet Fertil 2002; 30: 562-5.
  20. Nicolaides KH. Nuchal translucency and other ?rst-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004;191:45-67.
  21. Souka Ap, Von Kaisenberg Cs, Hyett Ja, Sonek Jd, Nicolaides KH. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005;192:1005-21.
  22. Senat Mv, Frydman R. Hyperclarté nucale à caryotype normal. Gynecol Obstet fertilité 2007; 6: 507-15.
  23. Economides Dl, Braithwaite JM. First trimester ultrasonographic diagnosis of fetal structural abnormalities in a low risk population. Br J Obstet Gynaecol 1998; 105: 53-7.